U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
September 17, 2026
September 17, 2026
LEVERKUSEN, Germany, Sept. 17 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:
* * *
U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
*
Berlin, September 17, 2026 - Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Kerendia(tm) (finerenone), a selective, non-steroid . . .
* * *
U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
*
Berlin, September 17, 2026 - Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Kerendia(tm) (finerenone), a selective, non-steroid . . .